WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.

• Main Authors: Afif Ben Salah (Author), Pierre A Buffet (Author), Gloria Morizot (Author), Nathalie Ben Massoud (Author), Amor Zâatour (Author), Nissaf Ben Alaya (Author), Nabil Bel Haj Hamida (Author), Zaher El Ahmadi (Author), Matthew T Downs (Author), Philip L Smith (Author), Koussay Dellagi (Author), Max Grögl (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2009-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cutaneous leishmaniasis (cl) is a disfiguring disease that confronts clinicians with a quandary: leave patients untreated or engage in a complex or toxic treatment. Topical treatment of CL offers a practical and safe option. Accordingly, the treatment of CL with WR279,396, a formulation of paromomyc...